TRVI
Trevi Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -15.8% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 3.53M | $50.51M | n/a | n/a |
| Q2 2026 | 73 | -1 | 67.22M | $1.24B | +7 | −8 |
| Q1 2026 | 77 | +2 | 59.43M | $710.63M | +8 | −6 |
| Q4 2025 | 75 | 0 | 58.45M | $731.74M | +1 | −1 |
| Q3 2025 | 18 | 0 | 44.17M | $404.20M | n/a | n/a |
| Q2 2025 | 15 | 0 | 25.58M | $139.93M | +1 | −1 |
| Q1 2025 | 12 | 0 | 12.85M | $80.81M | +1 | −1 |
| Q4 2024 | 12 | +4 | 15.26M | $62.88M | +4 | n/a |
| Q3 2024 | 7 | +3 | 5.91M | $19.73M | +3 | n/a |
| Q2 2024 | 4 | n/a | 5.62M | $16.74M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 3.23M | -26.6% | $20.30M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 2 | Marshall Wace ✦ | 2.55M | +5851.0% | $16.07M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 3 | Point72 Asset Management ✦ | 2.37M | -42.9% | $14.89M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.61M | +24.3% | $10.16M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | State Street Global Advisors ✦ (passive) | 1.42M | +21.7% | $8.96M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Millennium Management ✦ | 823.25K | +356.3% | $5.18M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Adage Capital Partners ✦ | 440.00K | -82.4% | $2.77M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 127.45K | New | $801,673 | 0.0% | New | 1 | SEC ↗ ×2 |
| 9 | Two Sigma Investments ✦ | 117.74K | -13.3% | $740,559 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 88.90K | -11.4% | $559,181 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 32.16K | +27.8% | $203,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 27.72K | +20.4% | $174,359 | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Wellington Management | $801,673 | 0.0% |
Exited
| Citadel Advisors | $5.08M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 198 holders, 134.86M shares, $1.61B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 18.32K sh · $276,464
Director · 100 sh · $1,588
Director · 20.95K sh · $316,166
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology